A carregar...

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

The prevalence of cutaneous adverse events attributable to newly approved anti-cancer drugs has been well reviewed in the dermatologic literature. In contrast, over 75% of US Food and Drug Administration approvals in the past 5 years have been for non-cancer drugs and indications. This represents mu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drugs R D
Main Authors: Macklis, Paul C., Dulmage, Brittany, Evans, Brady, Rosenbach, Misha, Gudjonsson, Johann E., Kaffenberger, Benjamin H.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7419407/
https://ncbi.nlm.nih.gov/pubmed/32557274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40268-020-00311-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!